

April industrial output surprised on the upside at 6.2% yoy.

Selena Ling

Head of Research and Strategy

+65 6530 4887

LingSSSelena@ocbc.com



Highlights:

April industrial output surprised on the upside at 6.2% yoy (2.2% mom sa), boosted by transport engineering, electronics and general manufacturing output and in spite of weakness in biomedical (-1.1% yoy, mainly due to the drag from pharmaceuticals which fell 11.3% yoy) and chemicals (-3.4% yoy weighed down by petrochemicals amid plant maintenance shutdowns and soft regional demand). This is an improvement from the upwardly revised March performance of 5.1% yoy (-11.2% mom sa) and suggests that any immediate spillover effects from China's Covid-related lockdowns, growth slowdown and supply chain disruptions has been muted so far. Excluding biomedical manufacturing, industrial output contracted for the second straight month by 1.8% mom sa in April.

Singapore's manufacturing sector has been boosted by the robust global chip demand and improved aerospace MRO activities on the back of strong demand from 5G and data centres amid the global chip shortage as well as the lifting of air travel restrictions that have contributed to a surge in commercial airlines positioning for revenge travel respectively. These latter two factors should sustain in the coming months. Even the general manufacturing segment is benefiting from higher output of beverage products, milk products and animal feed which have been seeing increased demand.

The main segment that has underperformed recently is the biomedical sector, namely pharmaceuticals which could be possibly attributable to more countries treating Covid as endemic and hence waning the demand for test kits etc. The pharmaceutical sector output is notoriously volatile while the base is relatively high until August 2021, hence the pharmaceutical underperformance could continue for the next few months. The pharmaceutical industry output has declined 6.3% yoy in the first four months of this year.

Given that the first four months have recorded healthy manufacturing output growth, even if manufacturing momentum tapers in the coming months, there may be a slight upside risk to our full-year 2022 manufacturing growth forecast of 3.8% yoy. However, I would prefer to await for another 1-2 months of data for confirmation since the China slowdown story in 2Q and the global supply chain disruptions, partly attributable to the Russia-Ukraine conflict, as well as the aggressive monetary policy tightening by major central banks like the FOMC are still in play. Note that MTI had narrowed the 2022 GDP growth forecast from the original 3-5% to the lower half of the range at 3-4% yesterday despite the upward revision in 1Q GDP growth estimates.



Source: EDB

Treasury Research & Strategy

Macro Research

Selena Ling
Head of Research & Strategy
LingSSSelena@ocbc.com
Tommy Xie Dongming
Head of Greater China Research
XieD@ocbc.com
Wellian Wiranto
Malaysia & Indonesia
WellianWiranto@ocbc.com
Howie Lee
Thailand & Commodities
HowieLee@ocbc.com
Herbert Wong
Hong Kong & Macau
herberhtwong@ocbcwh.com

FX/Rates Strategy

Frances Cheung
Rates Strategist
FrancesCheung@ocbc.com
Terence Wu
FX Strategist
TerenceWu@ocbc.com

Credit Research

Andrew Wong
Credit Research Analyst
WongVKAM@ocbc.com
Ezien Hoo
Credit Research Analyst
EzienHoo@ocbc.com
Wong Hong Wei
Credit Research Analyst
WongHongWei@ocbc.com
Toh Su N
Credit Research Analyst
Tohsn@ocbc.com

This publication is solely for information purposes only and may not be published, circulated, reproduced or distributed in whole or in part to any other person without our prior written consent. This publication should not be construed as an offer or solicitation for the subscription, purchase or sale of the securities/instruments mentioned herein. Any forecast on the economy, stock market, bond market and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the securities/instruments. Whilst the information contained herein has been compiled from sources believed to be reliable and we have taken all reasonable care to ensure that the information contained in this publication is not untrue or misleading at the time of publication, we cannot guarantee and we make no representation as to its accuracy or completeness, and you should not act on it without first independently verifying its contents. The securities/instruments mentioned in this publication may not be suitable for investment by all investors. Any opinion or estimate contained in this report is subject to change without notice. We have not given any consideration to and we have not made any investigation of the investment objectives, financial situation or particular needs of the recipient or any class of persons, and accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the recipient or any class of persons acting on such information or opinion or estimate.

This publication may cover a wide range of topics and is not intended to be a comprehensive study or to provide any recommendation or advice on personal investing or financial planning. Accordingly, they should not be relied on or treated as a substitute for specific advice concerning individual situations. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase the investment product. OCBC Bank, its related companies, their respective directors and/or employees (collectively "Related Persons") may or might have in the future interests in the investment products or the issuers mentioned herein. Such interests include effecting transactions in such investment products, and providing broking, investment banking and other financial services to such issuers. OCBC Bank and its Related Persons may also be related to, and receive fees from, providers of such investment products. There may be conflicts of interest between OCBC Bank, Bank of Singapore Limited, OCBC Investment Research Private Limited, OCBC Securities Private Limited or other members of the OCBC Group and any of the persons or entities mentioned in this report of which OCBC Bank and its analyst(s) are not aware due to OCBC Bank's Chinese Wall arrangement.

This report is intended for your sole use and information. By accepting this report, you agree that you shall not share, communicate, distribute, deliver a copy of or otherwise disclose in any way all or any part of this report or any information contained herein (such report, part thereof and information, "Relevant Materials") to any person or entity (including, without limitation, any overseas office, affiliate, parent entity, subsidiary entity or related entity) (any such person or entity, a "Relevant Entity") in breach of any law, rule, regulation, guidance or similar. In particular, you agree not to share, communicate, distribute, deliver or otherwise disclose any Relevant Materials to any Relevant Entity that is subject to the Markets in Financial Instruments Directive (2014/65/EU) ("MiFID") and the EU's Markets in Financial Instruments Regulation (600/2014) ("MiFIR") (together referred to as "MiFID II"), or any part thereof, as implemented in any jurisdiction. No member of the OCBC Group shall be liable or responsible for the compliance by you or any Relevant Entity with any law, rule, regulation, guidance or similar (including, without limitation, MiFID II, as implemented in any jurisdiction).

Co.Reg.no.:193200032W